Clinical Trial Update: Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating whether adding immunoglobulin and prednisolone reduces coronary artery lesions in Kawasaki disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kawasaki Disease

Drugs mentioned

• Intravenous Immunoglobulin (IVIG)
• Prednisolone (Prednisolone)

Snippet

Sponsor: Children's Hospital of Fudan University | Conditions: Kawasaki Disease | Phase 3 | Status: COMPLETED